Antiviral and Immunotherapy for Chronic Hepatitis B
Part of Digestive system, Infections clinical trials.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had a positive test for hepatitis B surface antigen (HBsAg) or HBV DNA for more than 6 months.
- You are currently in the immune clearance phase: HBeAg positive, HBV DNA positive, and your ALT level is above 40 U/L.
- You have not received any previous treatment for hepatitis B.
- You do not have cirrhosis or liver cancer, and you do not have serious heart disease, uncontrolled seizures, or other major health conditions like uncontrolled diabetes or autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This trial tests a new way to treat chronic hepatitis B in patients already taking antiviral medication. It combines a drug that helps the immune system fight the virus with another drug that boosts the immune response, aiming to improve chances of clearing the virus.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
This study tests whether a combination of two drugs (ASC22 and Peg-IFN) can help people with chronic hepatitis B achieve a functional cure. The goal is to see if this therapy can clear the virus and improve liver health.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.